Ab0511 systemic lupus erythematosus disease activity score (sle- das) validation in argentinian patients

Background Many activity indices have been developed for Systemic Lupus Erythematosus. However, they present important limitations due to the multi-organ compromise. The SLEDAI score and its different versions are widely used in daily practice and in clinical research. Diogo Jesus et al (2018) developed the SLE-DAS (Systemic Lupus Erythematosus Disease Activity Score), that include 17 items, 4 of them continuous. SLE-DAS assesses disease activity in the 28 previous days using an online calculator, with clinical characteristics non-evaluated by SLEDAI. It showed greater precision to measure disease activity, greater sensitivity to detect clinically significant changes and better performance to predict accumulated damage than SLEDAI. It has not yet been validated in Argentina. Objectives To determine the validity of the SLE-DAS score in a population of patients with SLE from Argentina. Methods A multicenter observational study was conducted. Outpatients and hospitalized patients with SLE from 9 Argentinian centers were included between July to August 2021. Socio-demographic and disease variables were studied and SLE activity was measured by physician’s global assessment (PGA), SLEDAI 2K and SLE-DAS. The disease activity categories used for SLE-DAS were: remission ≤2.08; mild activity >2.08 to 7.10, moderate and severe activity >7.10. For SLEDAI 2K, remission was considered 0, mild activity 1 to 5, moderate 6 to 10, high 11 to 19, very high >20 points. To determine construct validity and criterion validity, SLEDAI 2K and PGA were used as the gold standard and correlation between scores was analyzed with the Pearson and Spearman correlation coefficient. Sensitivity and specificity of the points that define each of the activity levels were established by ROC curves to determine the discriminative capacity of SLE-DAS. Results A multicenter observational study was conducted. Outpatients and hospitalized patients with SLE from 9 Argentinian centers were included between July to August 2021. Socio-demographic and disease variables were studied and SLE activity was measured by physician’s global assessment (PGA), SLEDAI 2K and SLE-DAS. The disease activity categories used for SLE-DAS were: remission ≤2.08; mild activity >2.08 to 7.10, moderate and severe activity >7.10. For SLEDAI 2K, remission was considered 0, mild activity 1 to 5, moderate 6 to 10, high 11 to 19, very high >20 points. To determine construct validity and criterion validity, SLEDAI 2K and PGA were used as the gold standard and correlation between scores was analyzed with the Pearson and Spearman correlation coefficient. Sensitivity and specificity of the points that define each of the activity levels were established by ROC curves to determine the discriminative capacity of SLE-DAS. Conclusion In this population of lupus patients from Argentina, the SLE-DAS allowed to discriminate between remission and disease activity, being a useful and practical tool. Disclosure of Interests None declared